Info

NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company engaged in the development of specialty therapeutics to treat gastrointestinal (GI) and endocrine disorders with unmet medical need. As of April 15, 2008, the Company was advancing two late-stage programs GATTEX (teduglutide) is in Phase III clinical development for intestinal failure associated with short bowel syndrome and NPSP558, parathyroid hormone 1-84 (recombinant deoxyribonucleic acid (rDNA) origin) injection, is in Phase II clinical development as a hormone therapy for hypoparathyroidism. NPS has also completed a Phase III osteoporosis study for PREOS (parathyroid hormone 1-84 (rDNA origin) injection). NPS complements its internal programs with partnerships with Amgen, GlaxoSmithKline, Kirin and Nycomed.